US · Healthcare · Biotechnology
EPS came in at 0.08 against a street estimate of -0.08 — a beat of 200.0%.
Analysts rate Anavex Life Sciences Corp a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $20.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.69% |
| Vanguard Capital Management, LLC | 4.37% |
| Two Sigma Investments LLC | 3.29% |
| Geode Capital Management, LLC | 2.60% |
| State Street Corp | 2.07% |
| Federated Hermes Inc | 1.16% |
| AQR Capital Management LLC | 1.04% |
| Vanguard Portfolio Management, LLC | 1.02% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Anavex Life Sciences Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.